Market Overview:
The global human coagulation factor â…§ market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The recombinant factor VIII segment is expected to dominate the market during the forecast period, owing to its high demand and increasing adoption in developed countries. The hemophilia A segment is projected to be the fastest growing segment during the forecast period, owing to rising incidence of hemophilia A cases across the globe. North America dominates the global human coagulation factor â…§ market with a share of more than 38%, followed by Europe and Asia Pacific respectively.
Product Definition:
Human Coagulation Factor VIII is a glycoprotein that helps to form clots by binding to and activating another clotting factor, Factor X. It is important for the prevention of excessive bleeding.
Recombinant Factor VIII:
Recombinant factor VIII (rFVIII) is a blood clotting factor manufactured by recombinant DNA technology. It is intended for the treatment of hemophilia A and B, which are caused by a lack of proper coagulation factors in the body. rFVIII has been approved in Europe and Japan for treatment of both hemophilia A & B as well as severe chronic idiopathic thrombocytopenic purpura (ITP).
Human Factor VIII:
Human coagulation factor VIII (FXIII) is a protein that facilitates the normal functioning of the blood clotting process. In hemophilia A, there is a deficiency or absence of functional FXIII proteins in the blood. Human coagulation factor VIII (FXIII) market consists of products such as recombinant human fibrinogen and recombinant human thrombin which are used to treat Hemophilia A and B respectively.
Application Insights:
On the basis of application, the global human coagulation factor market is segmented into hemophilia A, hemophilia B, and other bleeding disorders. Hemophilia A held the largest share in terms of revenue in 2017 due to increasing prevalence rates coupled with rising awareness about inheritance bleeding disorders. According to a study published by National Center for Biotechnology Information (NCBI) in March 2018, around 1:600 men are suffering from hereditary deficiency of Factor VIII or F8 protein which causes severe hemorrhage during physical injury.
The other bleeding disorders segment is expected to grow at fastest rate over forecast period owing to high unmet medical needs and growing incidence rates associated with various types of bleeds such as nosebleed, leg ulcers & varicose vein problems among others.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in prevalence of bleeding disorders, increasing adoption of costlier treatment options, and rising awareness about these diseases. Moreover, presence of key players such as Pfizer Inc.; CSL; Baxter International; and AbbVie Inc. is also expected to drive the regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period due to factors such as improving healthcare infrastructure & availability of advanced products for coagulation disorders coupled with growing patient awareness levels regarding available treatment options for various conditions at an affordable price range.
Growth Factors:
- Increasing incidence of bleeding disorders: The global human coagulation factor â…§ market is expected to grow at a CAGR of 5.5% during the forecast period due to the increasing incidence of bleeding disorders such as hemophilia and von Willebrand disease.
- Growing demand for recombinant products: The growth of the human coagulation factor â…§ market is also attributed to the growing demand for recombinant products, which are safer and more effective than their natural counterparts.
- Technological advancements in gene therapy: The advent of gene therapy has revolutionized the treatment options for patients with bleeding disorders, thereby driving the growth of the human coagulation factor â…§ market.
- Rising awareness about blood clotting disorders: There is a growing awareness among people about blood clotting disorders, which is helping to drive demand for better diagnosis and treatment options for these conditions. This is likely to boost growth prospects for the global human coagulation factor â…§ market in coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Human Coagulation Factor Ⅷ Market Research Report
By Type
Recombinant Factor VIII, Human Factor VIII
By Application
Hemophilia A, Relvent Bleeding Diseases
By Companies
Bayer, CSL Behring, Baxter, Grifols, Octapharma, Pfizer, Taibang Bio, Shanghai Laishi, Hualan Bio, Guangdong Shuanglin, GreenCross
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
182
Number of Tables & Figures
128
Customization Available
Yes, the report can be customized as per your need.
Global Human Coagulation Factor Ⅷ Market Report Segments:
The global Human Coagulation Factor Ⅷ market is segmented on the basis of:
Types
Recombinant Factor VIII, Human Factor VIII
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hemophilia A, Relvent Bleeding Diseases
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- CSL Behring
- Baxter
- Grifols
- Octapharma
- Pfizer
- Taibang Bio
- Shanghai Laishi
- Hualan Bio
- Guangdong Shuanglin
- GreenCross
Highlights of The Human Coagulation Factor Ⅷ Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Recombinant Factor VIII
- Human Factor VIII
- By Application:
- Hemophilia A
- Relvent Bleeding Diseases
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Coagulation Factor Ⅷ Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Human coagulation factor â…§ is a protein that helps to regulate the clotting process in the body. This protein helps to activate other proteins involved in blood clotting, and it also helps to prevent blood from flowing out of vessels too quickly.
Some of the major players in the human coagulation factor â…§ market are Bayer, CSL Behring, Baxter, Grifols, Octapharma, Pfizer, Taibang Bio, Shanghai Laishi, Hualan Bio, Guangdong Shuanglin, GreenCross.
The human coagulation factor ¢€¦§ market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Coagulation Factor Ⅷ Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Coagulation Factor Ⅷ Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Coagulation Factor Ⅷ Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Coagulation Factor Ⅷ Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Coagulation Factor Ⅷ Market Size & Forecast, 2020-2028
4.5.1 Human Coagulation Factor Ⅷ Market Size and Y-o-Y Growth
4.5.2 Human Coagulation Factor Ⅷ Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Recombinant Factor VIII
5.2.2 Human Factor VIII
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hemophilia A
6.2.2 Relvent Bleeding Diseases
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Human Coagulation Factor Ⅷ Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Human Coagulation Factor Ⅷ Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Recombinant Factor VIII
9.6.2 Human Factor VIII
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hemophilia A
9.10.2 Relvent Bleeding Diseases
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Recombinant Factor VIII
10.6.2 Human Factor VIII
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hemophilia A
10.10.2 Relvent Bleeding Diseases
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Recombinant Factor VIII
11.6.2 Human Factor VIII
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hemophilia A
11.10.2 Relvent Bleeding Diseases
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Recombinant Factor VIII
12.6.2 Human Factor VIII
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hemophilia A
12.10.2 Relvent Bleeding Diseases
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Recombinant Factor VIII
13.6.2 Human Factor VIII
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hemophilia A
13.10.2 Relvent Bleeding Diseases
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Human Coagulation Factor Ⅷ Market: Competitive Dashboard
14.2 Global Human Coagulation Factor Ⅷ Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 CSL Behring
14.3.3 Baxter
14.3.4 Grifols
14.3.5 Octapharma
14.3.6 Pfizer
14.3.7 Taibang Bio
14.3.8 Shanghai Laishi
14.3.9 Hualan Bio
14.3.10 Guangdong Shuanglin
14.3.11 GreenCross
